1.Guo Y，Tian Y，Wang H，et al. Prevalence，incidence，and lifetime risk of atrial fibrillation in China：new insights into the global burden of atrial fibrillation［J］. CHEST Journal，2015，147（1）：109-119.

2.Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials［J］. Arch Intern Med，1994，154（13）：1449-1457.

3.Guo Y，Apostolakis S，Blann AD，et al. Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chinese patients with atrial fibrillation［J］. Int J Cardiol，2013，168（2）：904-909.

4.Connolly SJ，Ezekowitz MD，Yusuf S，et al. Dabigatran versus warfarin in patients with atrial fibrillation［J］. N Engl J Med，2009，361（12）：1139-1151.

5.Patel MR，Mahaffey KW，Garg J，et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation［J］. N Engl J Med，2011，365（10）：883-891.

6.Connolly SJ，Eikelboom J，Joyner C，et al. Apixaban in patients with atrial fibrillation［J］. N Engl J Med，2011，364（9）：806-817.

7.Giugliano RP，Ruff CT，Braunwald E，et al. Edoxaban versus warfarin in patients with atrial fibrillation［J］. N Engl J Med，2013，369（22）：2093-2104.

8.中华心血管病杂志血栓循证工作组. 非瓣膜病心房颤动患者应用新型口服抗凝药物中国专家建议［J］.中华心血管病杂志，2014，42（5）：362-369.

9.Zhao J，Su YY，Zhang Y，et al. Decompressive hemicraniectomy in malignant middle cerebral artery infarct：a randomized controlled trial enrolling patients up to 80 years old［J］. Neurocrit Care，2012，17（2）：161-171.

10.Vahedi K，Hofmeijer J，Juettler E，et al. Early decompressive surgery in malignant infarction of themiddle cerebral artery：a pooled analysis of three randomised controlled trials［J］. The Lancet Neurology，2007，6（3）：215-222.

11.Juttler E，Unterberg A，Woitzik J，et al. Hemicraniectomy in older patients with extensive middle-cerebral-artery stroke［J］. N Engl J Med，2014，370（12）：1091-1100.

12.中华医学会神经病学分会神经重症协作组，中国医师协会神经内科医师分会神经重症专委会. 大脑半球大面积梗死监护与治疗中国专家共识［J］. 中华医学杂志，2017，97（9）：645-652.